Bortezomib-based therapy for newly diagnosed multiple myeloma
patients ineligible for autologous stem cell transplantation:
Czech Registry Data

J 2021

Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

SANDECKÁ, Viera, Luděk POUR, Ivan SPICKA, Jiri MINARIK, Jakub RADOCHA et. al.

Basic information

Original name

Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

Authors

SANDECKÁ, Viera (703 Slovakia), Luděk POUR (203 Czech Republic), Ivan SPICKA (203 Czech Republic), Jiri MINARIK (203 Czech Republic), Jakub RADOCHA (203 Czech Republic), Tomas JELINEK (203 Czech Republic), Adriana HEINDORFER (203 Czech Republic), Petr PAVLICEK (203 Czech Republic), Michal SYKORA (203 Czech Republic), Alexandra JUNGOVA (203 Czech Republic), Petr KESSLER (203 Czech Republic), Marek WROBEL (203 Czech Republic), David STAROSTKA (203 Czech Republic), Jana ULLRYCHOVA (203 Czech Republic), Lukas STEJSKAL (203 Czech Republic), Martin ŠTORK (203 Czech Republic, guarantor), Jan STRAUB (203 Czech Republic), Tomas PIKA (203 Czech Republic), Lucie KUBÍNOVÁ (203 Czech Republic, belonging to the institution), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Vladimir MAISNAR (203 Czech Republic) and Roman HAJEK (203 Czech Republic)

Edition

European Journal of Haematology, Hoboken, Wiley-Blackwell, 2021, 0902-4441

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.674

RIV identification code

RIV/00216224:14110/21:00123612

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/ejh.13683

UT WoS

000678205200001

Keywords in English

bortezomib; multiple myeloma; patient; treatment

Abstract

V originále

Objectives This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible. Patients and Methods We analyzed data from the Registry of Monoclonal Gammopathies (RMG) of the Czech Myeloma Group (CMG) to provide real-world evidence of outcome for 794 newly diagnosed MM transplant ineligible patients. The most frequently used regimen was VCd (bortezomib-cyclophosphamide-dexamethasone) (47.5%) over VMP (bortezomib-melphalan-prednisone) (21.7%), BDd (bortezomib-doxorubicin-dexamethasone) (9.8%), and VTd (bortezomib-thalidomide-dexamethasone) (2.9%). Results The overall response rate (ORR) was 69.2% (478/691), including 12.6% (>= CR); 34.7% very good partial responses (VGPR); and 21.9% partial responses (PR). Among triplet regimens, VMP was the most effective regimen compared to VCd, BDd, and VTd. Median PFS was 22.3 vs. 18.5 vs. 13.7 vs. 13.8 mo, (P = .275), respectively, and median OS was 49 vs. 41.7 vs. 37.9 vs. 32.2 mo (P = .004), respectively. The most common grade 3-4 toxicities were anemia in 17.4% and infections in 18% of patients. Conclusion Our study confirmed that bortezomib-based treatment is effective and safe in NDMM transplant ineligible patients, especially VMP, which was identified as superior between bortezomib-based induction regimens not only in clinical trials, but also in real clinical practice.

Citovat

SANDECKÁ, Viera, Luděk POUR, Ivan SPICKA, Jiri MINARIK, Jakub RADOCHA, Tomas JELINEK, Adriana HEINDORFER, Petr PAVLICEK, Michal SYKORA, Alexandra JUNGOVA, Petr KESSLER, Marek WROBEL, David STAROSTKA, Jana ULLRYCHOVA, Lukas STEJSKAL, Martin ŠTORK, Jan STRAUB, Tomas PIKA, Lucie KUBÍNOVÁ, Sabina ŠEVČÍKOVÁ, Vladimir MAISNAR and Roman HAJEK. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. European Journal of Haematology. Hoboken: Wiley-Blackwell, 2021, vol. 107, No 4, p. 466-474. ISSN 0902-4441. Available from: https://dx.doi.org/10.1111/ejh.13683.

@article{1818698,
   author = {Sandecká, Viera and Pour, Luděk and Spicka, Ivan and Minarik, Jiri and Radocha, Jakub and Jelinek, Tomas and Heindorfer, Adriana and Pavlicek, Petr and Sykora, Michal and Jungova, Alexandra and Kessler, Petr and Wrobel, Marek and Starostka, David and Ullrychova, Jana and Stejskal, Lukas and Štork, Martin and Straub, Jan and Pika, Tomas and Kubínová, Lucie and Ševčíková, Sabina and Maisnar, Vladimir and Hajek, Roman},
   article_location = {Hoboken},
   article_number = {4},
   doi = {http://dx.doi.org/10.1111/ejh.13683},
   keywords = {bortezomib; multiple myeloma; patient; treatment},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/ejh.13683},
   volume = {107},
   year = {2021}
}

TY  - JOUR
ID  - 1818698
AU  - Sandecká, Viera - Pour, Luděk - Spicka, Ivan - Minarik, Jiri - Radocha, Jakub - Jelinek, Tomas - Heindorfer, Adriana - Pavlicek, Petr - Sykora, Michal - Jungova, Alexandra - Kessler, Petr - Wrobel, Marek - Starostka, David - Ullrychova, Jana - Stejskal, Lukas - Štork, Martin - Straub, Jan - Pika, Tomas - Kubínová, Lucie - Ševčíková, Sabina - Maisnar, Vladimir - Hajek, Roman
PY  - 2021
TI  - Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data
JF  - European Journal of Haematology
VL  - 107
IS  - 4
SP  - 466-474
EP  - 466-474
PB  - Wiley-Blackwell
SN  - 09024441
KW  - bortezomib
KW  - multiple myeloma
KW  - patient
KW  - treatment
UR  - https://onlinelibrary.wiley.com/doi/10.1111/ejh.13683
N2  - Objectives This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible. Patients and Methods We analyzed data from the Registry of Monoclonal Gammopathies (RMG) of the Czech Myeloma Group (CMG) to provide real-world evidence of outcome for 794 newly diagnosed MM transplant ineligible patients. The most frequently used regimen was VCd (bortezomib-cyclophosphamide-dexamethasone) (47.5%) over VMP (bortezomib-melphalan-prednisone) (21.7%), BDd (bortezomib-doxorubicin-dexamethasone) (9.8%), and VTd (bortezomib-thalidomide-dexamethasone) (2.9%). Results The overall response rate (ORR) was 69.2% (478/691), including 12.6% (>= CR); 34.7% very good partial responses (VGPR); and 21.9% partial responses (PR). Among triplet regimens, VMP was the most effective regimen compared to VCd, BDd, and VTd. Median PFS was 22.3 vs. 18.5 vs. 13.7 vs. 13.8 mo, (P = .275), respectively, and median OS was 49 vs. 41.7 vs. 37.9 vs. 32.2 mo (P = .004), respectively. The most common grade 3-4 toxicities were anemia in 17.4% and infections in 18% of patients. Conclusion Our study confirmed that bortezomib-based treatment is effective and safe in NDMM transplant ineligible patients, especially VMP, which was identified as superior between bortezomib-based induction regimens not only in clinical trials, but also in real clinical practice.
ER  -

SANDECKÁ, Viera, Luděk POUR, Ivan SPICKA, Jiri MINARIK, Jakub RADOCHA, Tomas JELINEK, Adriana HEINDORFER, Petr PAVLICEK, Michal SYKORA, Alexandra JUNGOVA, Petr KESSLER, Marek WROBEL, David STAROSTKA, Jana ULLRYCHOVA, Lukas STEJSKAL, Martin ŠTORK, Jan STRAUB, Tomas PIKA, Lucie KUBÍNOVÁ, Sabina ŠEVČÍKOVÁ, Vladimir MAISNAR and Roman HAJEK. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. \textit{European Journal of Haematology}. Hoboken: Wiley-Blackwell, 2021, vol.~107, No~4, p.~466-474. ISSN~0902-4441. Available from: https://dx.doi.org/10.1111/ejh.13683.

Detailed Information on Publication Record